Mangalore Chemicals & Fertilizers Limited (NSE:MANGCHEFER)
India · Delayed Price · Currency is INR 359.00
+5.15 (1.46%)
Aug 1, 2025, 3:30 PM IST
Revance Therapeutics Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
| 33,800 | 33,319 | 37,954 | 36,415 | 28,956 | 21,440 | Upgrade | |
Revenue Growth (YoY) | -7.43% | -12.21% | 4.23% | 25.76% | 35.05% | -20.91% | Upgrade |
Cost of Revenue | 19,677 | 18,949 | 24,004 | 24,080 | 18,351 | 14,064 | Upgrade |
Gross Profit | 14,123 | 14,370 | 13,951 | 12,335 | 10,605 | 7,377 | Upgrade |
Selling, General & Admin | 725.7 | 714.77 | 725.55 | 739.56 | 750.57 | 737.41 | Upgrade |
Other Operating Expenses | 10,126 | 10,436 | 9,142 | 8,219 | 7,408 | 4,340 | Upgrade |
Operating Expenses | 11,606 | 11,912 | 10,583 | 9,555 | 8,664 | 5,769 | Upgrade |
Operating Income | 2,517 | 2,458 | 3,368 | 2,780 | 1,941 | 1,608 | Upgrade |
Interest Expense | -680.61 | -763.96 | -923.54 | -870.28 | -397.15 | -684.3 | Upgrade |
Interest & Investment Income | - | - | 329.17 | 252.22 | 192.84 | 211.73 | Upgrade |
Currency Exchange Gain (Loss) | - | - | -55.96 | -180.07 | -242.61 | 13.3 | Upgrade |
Other Non Operating Income (Expenses) | 372.5 | 366.47 | -240.83 | -169.95 | -92.63 | -73.31 | Upgrade |
EBT Excluding Unusual Items | 2,209 | 2,060 | 2,477 | 1,812 | 1,401 | 1,075 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | -57.78 | -52.2 | -54.88 | -22.61 | Upgrade |
Asset Writedown | - | - | -12.02 | - | - | - | Upgrade |
Pretax Income | 2,209 | 2,060 | 2,407 | 1,760 | 1,347 | 1,056 | Upgrade |
Income Tax Expense | 595.03 | 623.34 | 858.55 | 413.71 | 467.99 | 384.62 | Upgrade |
Net Income | 1,614 | 1,437 | 1,548 | 1,347 | 878.61 | 670.99 | Upgrade |
Net Income to Common | 1,614 | 1,437 | 1,548 | 1,347 | 878.61 | 670.99 | Upgrade |
Net Income Growth | 8.03% | -7.17% | 14.97% | 53.26% | 30.94% | 3.94% | Upgrade |
Shares Outstanding (Basic) | 118 | 118 | 119 | 119 | 119 | 119 | Upgrade |
Shares Outstanding (Diluted) | 118 | 118 | 119 | 119 | 119 | 119 | Upgrade |
Shares Change (YoY) | -0.13% | -0.03% | - | - | - | - | Upgrade |
EPS (Basic) | 13.63 | 12.13 | 13.06 | 11.36 | 7.41 | 5.66 | Upgrade |
EPS (Diluted) | 13.63 | 12.13 | 13.06 | 11.36 | 7.41 | 5.66 | Upgrade |
EPS Growth | 8.17% | -7.12% | 14.96% | 53.31% | 30.92% | 3.91% | Upgrade |
Free Cash Flow | - | 1,824 | 3,982 | -1,132 | -2,569 | 8,633 | Upgrade |
Free Cash Flow Per Share | - | 15.39 | 33.60 | -9.55 | -21.68 | 72.84 | Upgrade |
Dividend Per Share | - | 1.500 | 1.500 | 1.500 | 1.200 | 1.000 | Upgrade |
Dividend Growth | - | - | - | 25.00% | 20.00% | 100.00% | Upgrade |
Gross Margin | 41.78% | 43.13% | 36.76% | 33.87% | 36.63% | 34.41% | Upgrade |
Operating Margin | 7.45% | 7.38% | 8.87% | 7.63% | 6.70% | 7.50% | Upgrade |
Profit Margin | 4.78% | 4.31% | 4.08% | 3.70% | 3.03% | 3.13% | Upgrade |
Free Cash Flow Margin | - | 5.47% | 10.49% | -3.11% | -8.87% | 40.26% | Upgrade |
EBITDA | 3,294 | 3,219 | 4,067 | 3,360 | 2,428 | 2,092 | Upgrade |
EBITDA Margin | 9.75% | 9.66% | 10.71% | 9.23% | 8.39% | 9.76% | Upgrade |
D&A For EBITDA | 776.7 | 761.17 | 699.02 | 580.23 | 487.36 | 484.29 | Upgrade |
EBIT | 2,517 | 2,458 | 3,368 | 2,780 | 1,941 | 1,608 | Upgrade |
EBIT Margin | 7.45% | 7.38% | 8.87% | 7.63% | 6.70% | 7.50% | Upgrade |
Effective Tax Rate | 26.93% | 30.25% | 35.67% | 23.50% | 34.75% | 36.44% | Upgrade |
Revenue as Reported | 34,173 | 33,685 | 38,367 | 36,722 | 29,199 | 21,707 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.